122 related articles for article (PubMed ID: 15542372)
1. Candidate epitope identification using peptide property models: application to cancer immunotherapy.
Sung MH; Simon R
Methods; 2004 Dec; 34(4):460-7. PubMed ID: 15542372
[TBL] [Abstract][Full Text] [Related]
2. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design.
Schiewe AJ; Haworth IS
J Mol Graph Model; 2007 Oct; 26(3):667-75. PubMed ID: 17493854
[TBL] [Abstract][Full Text] [Related]
3. Expression mapping using a retroviral vector for CD8+ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by H2-Dd.
Aoshi T; Suzuki M; Uchijima M; Nagata T; Koide Y
J Immunol Methods; 2005 Mar; 298(1-2):21-34. PubMed ID: 15847794
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
5. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
6. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
7. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
8. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
9. A structure-based approach for prediction of MHC-binding peptides.
Altuvia Y; Margalit H
Methods; 2004 Dec; 34(4):454-9. PubMed ID: 15542371
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
[TBL] [Abstract][Full Text] [Related]
11. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
Singh R; Paterson Y
Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
[TBL] [Abstract][Full Text] [Related]
12. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes.
Houghton CS; Engelhorn ME; Liu C; Song D; Gregor P; Livingston PO; Orlandi F; Wolchok JD; McCracken J; Houghton AN; Guevara-Patiño JA
Vaccine; 2007 Jul; 25(29):5330-42. PubMed ID: 17570567
[TBL] [Abstract][Full Text] [Related]
13. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
15. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
16. Proteins accessible to immune surveillance show significant T-cell epitope depletion: Implications for vaccine design.
Halling-Brown M; Shaban R; Frampton D; Sansom CE; Davies M; Flower D; Duffield M; Titball RW; Brusic V; Moss DS
Mol Immunol; 2009 Aug; 46(13):2699-705. PubMed ID: 19560824
[TBL] [Abstract][Full Text] [Related]
17. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
18. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
19. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
20. Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications.
Brusic V; Bajic VB; Petrovsky N
Methods; 2004 Dec; 34(4):436-43. PubMed ID: 15542369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
